Trial Profile

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions

24 Jun 2025 Status changed from recruiting to discontinued.
27 Apr 2025 Planned End Date changed from 30 Jun 2025 to 30 Dec 2025.
27 Mar 2025 According to an AIM ImmunoTech media release, completion of enrollment expected Q2 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com